Sorafenib FDA Link

A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy.

Also Known As:

BAY 43-9006; Nexavar; 4- (4- (3- (4- Chloro- 3- trifluoromethylphenyl)ureido)phenoxy)pyridine- 2- carboxylic acid methyamide-4-methylbenzenesulfonate; BAY 545-9085; BAY-545-9085; BAY-673472; Sorafenib N-Oxide; Sorafenib Tosylate; BAY 43 9006; BAY 439006; BAY 545 9085; BAY 5459085; BAY 673472; BAY5459085; Sorafenib N Oxide; 2-Pyridinecarboxamide, 4- (4- ((((4- chloro- 3- (trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)- N- methyl-

Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - Phenylurea Compounds: 1
      - Sorafenib: 7178
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenylurea Compounds: 1
        Sorafenib: 7178
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Nicotinic Acids: 13
      - Niacinamide: 2223
        Sorafenib: 7178
- Heterocyclic Acids
  - Nicotinic Acids: 13
    - Niacinamide: 2223
      - Sorafenib: 7178

Rachel Farley-Loftus Selected Research

Rachel Farley-Loftus Research Topics

Disease

Drug/Important Bio-Agent (IBA)